HUBBARD, OH--(Marketwire - May 18, 2010) - NanoLogix, Inc. (PINKSHEETS: NNLX) announces advancements to its go-to-market strategy, including the exploration of its BNP/BNF technologies by the University of Texas - Texas Medical Center. To facilitate its entry into a wide range of sectors and markets, NanoLogix also announces it has retained Technica Communications for marketing and public relations services. In addition, the company will return for a third year to exhibit at the American Society of Microbiology (ASM) General Meeting, being held in San Diego at the end of May.
Physicians and other medical personnel at the University of Texas - Texas Medical Center in Houston began last September to explore Obstetrics applications for NanoLogix BNP/BNF technology. This week Medical Center personnel are undertaking work to determine the smallest amount of Group B Streptococcus (GBS) identifiable and the shortest test time achievable through the use of NanoLogix BNF technology. Texas Medical Center physicians see the high-speed diagnostic capabilities of the NanoLogix technology as a key to faster detection of GBS in late term pregnancies.
GBS bacteria are found in roughly 30 percent of reproductive-age women. The health of both newborns and their mothers can be seriously endangered if the newborns are delivered before mothers with active GBS can be treated. Therefore, the Center for Disease Control (CDC) recommends all pregnant women be tested, amounting to roughly 4.3 million tests each year in the U.S. CDC guidelines recommend physicians test pregnant women for GBS in the final weeks of their term. The NanoLogix BNP/BNF technology works 6 times faster than traditional methods and can reduce the GBS detection and identification time from 72 hours to approximately 12 hours.
To expand the reach and visibility of NanoLogix and its technologies, Technica Communications has been retained to support the company's short and long term business goals. Founded by President Lisa Ann Pinkerton, Technica Communications teams former health science and environmental journalists with talented marketing communications professionals, to provide marketing and communications services, ranging from branding and media relations, to video production, social media campaigns and web development. Its strategically focused and results-oriented outreach will spotlight NanoLogix and its rapid detection technology in sectors and markets primed for the next generation of accurate, high-speed diagnostics.
At the 110th Annual American Society of Microbiology Meeting in San Diego, CA, (May 24th - 26th) at the San Diego Convention Center, NanoLogix CEO Bret Barnhizer and VP of Research and Development Dr. Sergey Gazenko will display the company's BNP™, BNC™, and BNF™ rapid detection and identification technologies at booth 1629. The ASM is the world's premier event for microbiology. Additional information can be found at http://gm.asm.org/.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in a multitude of infectious and non-infectious human diseases, including but not limited to tuberculosis, non-tuberculous mycobacterium (NTM), pneumonia, anthrax, and plague. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation. For more information, visit www.nanologix.com.
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.